A homegrown model for heart patients worldwide

EDBI Pte Ltd has been actively partnering companies transforming healthcare through digitalization, such as our homegrown Biofourmis, which has now received the FDA’s first ever Breakthrough Device designation for a heart failure digital therapeutic. This will bring the company significantly closer to delivering a new model of care to patients worldwide living with heart failure.


The FDA Breakthrough Device programme is created to help bring effective treatment of life-threatening or irreversibly debilitating conditions to market sooner, and BiovitalsHF is a perfect candidate for this programme due to its clinical importance and impact on a condition that is expected to cost $70 billion per year by 2030.